<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[Stories by Dylan Collins on Medium]]></title>
        <description><![CDATA[Stories by Dylan Collins on Medium]]></description>
        <link>https://medium.com/@DylanRJCollins?source=rss-fb1e37754ff4------2</link>
        <image>
            <url>https://cdn-images-1.medium.com/fit/c/150/150/0*3MG5cCpLjTUijDSc.jpg</url>
            <title>Stories by Dylan Collins on Medium</title>
            <link>https://medium.com/@DylanRJCollins?source=rss-fb1e37754ff4------2</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Sat, 21 Nov 2026 05:57:13 GMT</lastBuildDate>
        <atom:link href="https://medium.com/@DylanRJCollins/feed" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Preventing Disease: What Innovators Need to Know]]></title>
            <link>https://medium.com/@DylanRJCollins/prevention-b5ddd29e091d?source=rss-fb1e37754ff4------2</link>
            <guid isPermaLink="false">https://medium.com/p/b5ddd29e091d</guid>
            <category><![CDATA[prevention]]></category>
            <category><![CDATA[epidemiology]]></category>
            <category><![CDATA[diabetes]]></category>
            <category><![CDATA[health]]></category>
            <category><![CDATA[medicine]]></category>
            <dc:creator><![CDATA[Dylan Collins]]></dc:creator>
            <pubDate>Sat, 12 Nov 2016 09:49:13 GMT</pubDate>
            <atom:updated>2016-11-14T19:45:40.094Z</atom:updated>
            <content:encoded><![CDATA[<p><a href="https://en.wikipedia.org/wiki/Geoffrey_Rose_%28epidemiologist%29">Geoffrey Rose</a>’s famous words are a must know in any conversation about preventive medicine.</p><blockquote>It is better to be healthy than dead or ill. That is the beginning and the end of the <strong>only</strong> real argument in preventive medicine. It is sufficient.</blockquote><p>This year’s Rhodes Healthcare Forum — an initiative by the Rhodes Trust to convene Rhodes Scholars on a path to improve health — is focused on the growing expectation that innovations in healthcare will lead to improved health outcomes. Within this discourse a lot of attention is paid to innovations in disease prevention, and I want to add to this conversation by focusing our attention on three important aspects.[1]</p><h3>Prevention is Usually Not Cost Effective</h3><p>You may have heard that disease prevention is more cost effective than treatment — meaning it costs less to prevent a disease than to treat a disease.</p><p><em>This, however, is </em><a href="http://www.nejm.org/doi/full/10.1056/NEJMp0708558#t=article"><em>usually not true</em></a><em>.</em></p><p>Let’s consider a man named Joe and a simple catastrophic event — such as a heart attack. If Joe has a heart attack, there is no question it is expensive: ambulances, emergency rooms, cardiac surgery, rehabilitation, medications, etc. The argument goes that if we can prevent Joe from having a heart attack we can reduce the cost of caring for Joe, assuming that the prevention cost is less than the treatment cost.</p><p>Consider two possible outcomes when prevention is successful:</p><ul><li>Joe has a heart attack later in life and investments in prevention only <strong>delayed</strong> his heart attack — therefore the total cost is the cost of prevention plus the cost of treatment.</li><li>Joe never has a heart attack, but develops another disease that is more expensive to treat and impossible/expensive to prevent.</li></ul><p>The latter point is uncomfortable because it implies that <em>dead people are cheap patients</em>. Said differently, people who are alive cost money and <strong>the state of being alive is a risk factor for developing all diseases.</strong> When prevention efforts are successful, more people live and therefore more people at risk for other diseases.</p><p>A peculiar example of this is smoking cessation. Huge success in reducing tobacco consumption actually resulted in an <em>increase </em>in heart attacks. This is because non-heart-attack-smoking-attributable mortality (e.g. lung cancer) decreased so much that many people were living long enough to get heart attacks, whereas they would have otherwise been dead.</p><h3>Personalised Medicine is not a Solution</h3><p>The goal of personalised medicine is risk stratification —to identify and make decisions based on an <strong>individual</strong>’s risk, rather than assuming an individual is sufficiently similar to a population like them.</p><p>This is known as a <em>high-risk </em>approach to prevention, because the goal of prevention is to identify individuals who are at high risk of developing a disease and targeting them for treatment. This is appealing to clinicians and data nerds alike, but the high-risk approach to prevention offers little to reduce the overall burden of disease in a population.</p><p>Enter: the <strong>prevention paradox</strong>. The prevention paradox describes an epidemiological phenomenon where most disease cases in a population originate from those who are at low or medium risk, and few originate from people who are at high risk.</p><p>The majority of people in a population are medium to low risk. Very few people are at high risk. Because so few people are at high risk — although many of them do have heart attacks — overall they contribute only a small proportion of the total number of heart attacks in a population. (That is, a large proportion of a small population is often a smaller number than a small proportion of a very large population)</p><p>An example of the prevention paradox is <a href="https://en.wikipedia.org/wiki/Framingham_Risk_Score">cardiovascular disease (CVD) risk</a>, which is an estimate of an individual’s risk of having a heart attack or stroke in a given time period. The majority of a population is low or medium risk, and very few are at high risk. Most cases of CVD, however, originate from low or medium risk people. Although the probability of developing CVD is high in the high risk group, few cases of CVD at the population level originate from the high risk group since the proportion of the population that is high risk is so small.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*69QKhznjcRH31LpyH90VPg.jpeg" /><figcaption>Most people in a population are at low or medium risk for developing cardiovascular disease and relatively few are at high risk. The implications of this are that, in absolute terms, the most cases of cardiovascular disease originate from the low and medium risk categories of a population.</figcaption></figure><p><strong>The implications of the prevention paradox</strong> are that you are unlikely to impact the overall burden of disease in a population by targeting high risk individuals. This is not a limitation of the models we use to predict disease, but of the epidemiological approach to prevention.</p><p>So, then, do we target low and medium risk people for treatment? To most this feels inherently wrong by leading us down a path of medicalising normality — and as Rose so aptly wrote, ‘<em>to be preoccupied with health is unhealthy.’</em></p><h3>Population Interventions are Better But Not Perfect</h3><p>So where do we stand? The alternate approach to the high-risk strategy is a population-based strategy. These strategies do not seek to target <em>individuals</em>, but they attempt to reduce the risk of the entire population.</p><p>To be successful, population interventions must be radical in the sense that they target the root cause of disease. What’s paradoxical, though, is that targeting the root causes of disease becomes a political issue because the points of intervention are usually social and economic.</p><p>Consider that reducing the average cholesterol level of a population by just 10% can lead to a 20 to 30% reduction in heart attacks. A popular approach to achieve this would be health education, but it is unlikely to succeed because it addresses only the most distal determinants of health (i.e. the reason people have high cholesterol is not because they do not <em>know</em> it should be lower). It does not address the context in which people may exist (e.g. poverty), or their rational behaviours that lead them to having high cholesterol (e.g. purchasing affordable unhealthy food). Addressing the context as such could yield high returns, but its political nature reduces it feasibility and likelihood.</p><p>Or consider fluoridating water to prevent dental caries. Fluoridation of water indiscriminately reduces the risk of dental caries in an entire population — it is clearly the best option to reduce the overall burden of disease and to reduce health disparities. However, it is a highly political intervention, and one in which has failed to be implemented by many municipalities.</p><p>The political nature of population interventions are not their only downfall (for if it was, surely we could work around this?). Interventions also need to be culturally appropriate and acceptable (are you asking someone to behave different than their entire social network?), and the association between the risk factor and disease must be linear (perhaps it’s J-shaped or parabolic, such that lowering the population mean has associated harms, not only benefits).</p><h3>The Path Forward</h3><p>This is not an argument <em>against </em>preventive medicine, but a reminder that popular rationalisations (or business cases) for disease prevention — although well-intentioned — often overlook basic epidemiological principles. Those looking to innovate in preventive medicine should remember these three points:</p><ul><li>There is only one argument for preventive medicine, and it is not an argument of cost effectiveness, but a moral one.</li><li>Personalised medicine (i.e. individual risk assessment) is not a solution to reduce the overall burden of disease in a population.</li><li>Population interventions are best for reducing disease in a population, but are difficult to implement because they are political in nature and must be radical to succeed.</li></ul><p>And finally, those looking to make meaningful gains in this field must always remember the need for political engagement.</p><blockquote>The primary determinants of disease are mainly economic and social, and therefore its remedies must also be economic and social. <strong>Medicine and politics cannot and should not be kept apart. <br></strong>- Geoffrey Rose</blockquote><p>This piece draws mostly from Rose’s book on the <a href="https://www.amazon.co.uk/Roses-Strategy-Preventive-Medicine-Geoffrey/dp/0192630970">strategies of preventive medicine</a> — an absolute must-read for anyone working in this space or anyone who is concerned about my simplification of these arguments.</p><p>[1] There are, of course, exceptions to these principles.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=b5ddd29e091d" width="1" height="1" alt="">]]></content:encoded>
        </item>
    </channel>
</rss>